- In June 2024, Sinovac Biotech Ltd. announced that its PROVARIX (Varicella Vaccine (Vero Cell), Live) received approval from the China National Medical Products Administration (NMPA) for use in adolescents and adults aged 13 and older. The vaccine will follow a two-dose schedule for basic immunization, with doses administered 4 to 8 weeks apart. Previously, PROVARIX had only been approved for children aged 12 months to 12 years.
- In February 2023, GC Biopharma announced that the World Health Organization (WHO) had granted prequalification for its varicella vaccine, BARYCELA. This prequalification makes BARYCELA eligible for procurement by United Nations agencies, including the Pan American Health Organization (PAHO), for use in national immunization programs. BARYCELA is now one of three vaccines that GC Biopharma has received WHO prequalification for, alongside its H1N1 pandemic and seasonal influenza vaccines.
